Randomized phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients with MGMT promoter hypermethylation (Alliance A071102).

被引：0

作者：

Sarkaria, Jann Nagina

Ballman, Karla V.

Kizilbash, Sani Haider

Sulman, Erik P.

Giannini, Caterina

Mashru, Sandeep H.

Piccioni, David Eric

Friday, Bret Edward Buckley

Dixon, Jesse G.

Kabat, Brian

Laack, Nadia N.

Hu, Leland

Kumthekar, Priya

Ellingson, Benjamin M.

Anderson, S. Keith

Galanis, Evanthia

机构：

[1] Mayo Clin, Rochester, MN USA

[2] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA

[3] Mayo Clin, Div Med Oncol, Rochester, MN USA

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[5] NW Kaiser Permanente, Portland, OR USA

[6] Univ Calif San Diego, Moores Canc Ctr, Ctr Personalized Canc Therapy, San Diego, CA USA

[7] Univ Calif San Diego, Moores Canc Ctr, Div Hematol & Oncol, San Diego, CA USA

[8] SMDC, Duluth, MN USA

[9] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA

[10] Mayo Clin, Phoenix, AZ USA

[11] Univ Chicago, Alliance Protocol Operat Off, Chicago, IL USA

[12] Univ Calif Los Angeles, Brain Res Inst, Dept Radiol, Radiol, Los Angeles, CA USA

[13] Mayo Clin, Alliance Stat & Data Ctr, Rochester, MN USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

基金：

美国国家卫生研究院;

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2001

引用

页数：1

共 50 条

[41] GENOME-WIDE DNA METHYLATION PATTERNS IN VERTU: A RANDOMIZED PHASE II TRIAL OF VELIPARIB, RADIOTHERAPY AND TEMOZOLOMIDE IN PATIENTS WITH MGMT-UNMETHYLATED GLIOBLASTOMA
Sim, Hao-Wen
Lwin, Zarnie
Barnes, Elizabeth
McDonald, Kerrie
Koh, Eng-Siew
Rosenthal, Mark
Foote, Matthew
Back, Michael
Wheeler, Helen
Buckland, Michael
Walsh, Kyle
Fisher, Lauren
Leonard, Robyn
Hall, Merryn
Ashley, David
Yip, Sonia
Simes, John
Sulman, Erik
Khasraw, Mustafa
NEURO-ONCOLOGY, 2022, 24 : 81 - 81
[42] A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients
Lee, Eudocia Q.
Kaley, Thomas J.
Duda, Dan G.
Schiff, David
Lassman, Andrew B.
Wong, Eric T.
Mikkelsen, Tom
Purow, Benjamin W.
Muzikansky, Alona
Ancukiewicz, Marek
Huse, Jason T.
Ramkissoon, Shakti
Drappatz, Jan
Norden, Andrew D.
Beroukhim, Rameen
Weiss, Stephanie E.
Alexander, Brian M.
McCluskey, Christine S.
Gerard, Mary
Smith, Katrina H.
Jain, Rakesh K.
Batchelor, Tracy T.
Ligon, Keith L.
Wen, Patrick Y.
CLINICAL CANCER RESEARCH, 2015, 21 (16) : 3610 - 3618
[43] A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme
Rosenfeld, Myrna R.
Ye, Xiaobu
Supko, Jeffrey G.
Desideri, Serena
Grossman, Stuart A.
Brem, Steven
Mikkelson, Tom
Wang, Daniel
Chang, Yunyoung C.
Hu, Janice
McAfee, Quentin
Fisher, Joy
Troxel, Andrea
Piao, Shengfu
Heitjan, Daniel F.
Tan, Kay See
Pontiggia, Laura
O'Dwyer, Peter J.
Davis, Lisa E.
Amaravadi, Ravi K.
AUTOPHAGY, 2014, 10 (08) : 1359 - 1368
[44] Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: Protocol of a multicenter, randomized, open-label, controlled phase III trial (CENTRIC)
Stupp, R.
Van den Bent, M. J.
Erridge, S. G.
Reardon, D. A.
Hong, Y.
Wheeler, H.
Hegi, M.
Perry, J. R.
Picard, M.
Weller, M.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[45] PHASE II TRIAL OF HYPOFRACTIONATED INTENSITY-MODULATED RADIOTHERAPY WITH CONCURRENT AND ADJUVANT TEMOZOLOMIDE FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME
Chen, Changhu
Damek, Denise
Gaspar, Laurie E.
Ney, Douglas
Waziri, Allen
Lillehei, Kevin
Kavanagh, Brian D.
NEURO-ONCOLOGY, 2011, 13 : 128 - 128
[46] Phase II trial of bevacizumab and temozolomide for treatment of elderly patients with newly diagnosed glioblastoma.
Molaie, Donna
Lai, Albert
Ellingson, Benjamin M.
Thien Nguyen
Bahng, Hye Hyun
Filka, Emese
Green, Stacey
Pope, Whitney B.
Leng, Mei
Yong, William H.
Green, Richard M.
Polikoff, Jonathan
Spier, Liz
Iwamoto, Fabio Massaiti
Lassman, Andrew B.
Cloughesy, Timothy Francis
Nghiemphu, Phioanh Leia
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[47] Talampanel With Standard Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma: A Multicenter Phase II Trial
Grossman, Stuart A.
Ye, Xiaobu
Chamberlain, Marc
Mikkelsen, Tom
Batchelor, Tracy
Desideri, Serena
Piantadosi, Steven
Fisher, Joy
Fine, Howard A.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) : 4155 - 4161
[48] A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study).
Khasraw, Mustafa
McDonald, Kerrie Leanne
Rosenthal, Mark
Lwin, Zarnie
Ashley, David M.
Wheeler, Helen
Barnes, Elizabeth
Koh, Eng-Siew
Foote, Matthew C.
Buckland, Michael
Fisher, Lauren
Leonard, Robyn
Hall, Merryn
Yip, Sonia
Simes, John
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[49] Interim analysis of the randomized PATSGO trial evaluating the prolongation of adjuvant temozolomide in newly diagnosed glioblastoma patients.
Baurain, J.
Boterberg, T.
Devriendt, D.
Hammouch, F.
Cosnard, G.
Whenham, N.
Clement, P. M.
Mitine, C.
Renard, L.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[50] PHASE II TRIAL OF UPFRONT BEVACIZUMAB WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE AND ORAL TOPOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)
Ranjan, Tulika
Desjardins, Annick
Peters, Katherine B.
Alderson, Lloyd
Kirkpatrick, John
Herndon, James, II
Bailey, Leighann
Sampson, John
Friedman, Allan H.
Friedman, Henry
Vredenburgh, James J.
NEURO-ONCOLOGY, 2012, 14 : 79 - 79

← 1 2 3 4 5 →